-
Media ReleaseAnalysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media ReleaseNovartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media ReleaseNovartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
-
Media ReleaseFDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
-
Media ReleaseVideo: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
-
Media ReleaseVideo: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
-
Media ReleaseVideo: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
-
Media ReleaseRAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
-
Media ReleaseVideo: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
-
Media ReleaseEarly Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease